Day: May 28, 2020

Baltika teavitas 30. aprillil 2020 börsil avalikustatud saneerimiskava kokkuvõttes ja võlausaldajatele edastatud saneerimiskava täisversioonis täiendavate finantseeringute kaasamise võimalustest. Kredex saatis 30. aprillil 2020 AS-ile Baltika otsuse 4 miljoni euro suuruse laenu heakskiitmise  kohta ja ka ettevõtte enamusaktsionär KJK Fund SICAV-SIF on kinnitanud valmisolekut anda Baltikale täiendavalt laenu kuni neli miljonit eurot. Üheks laenude saamise eelduseks oli AS Baltika saneerimiskava kinnitamine.Kredex on hiljem teavitanud Baltikat, et laenu väljastamist arutab ka sihtasutuse nõukogu. Baltika informeerib investoreid, et  saatis väliskaubandus- ja infotehnoloogiaminister Raul Siemile ning Kredexi nõukogu esimehele ja majandusministeeriumi kantslerile Ando Leppimanile pöördumise, milles palub jätta jõusse Kredexi otsuse eraldada...

TORONTO, May 28, 2020 (GLOBE NEWSWIRE) — Galantas Gold Corporation (“Galantas” or the “Company”), the AIM and TSXV quoted gold producer and explorer is pleased to announce that concentrate processing has recommenced at its 100% owned gold mine, near Omagh, Northern Ireland.Staff operating the concentrate processing plant (mill) were earlier furloughed under a UK government grant scheme, regarding the Coronavirus pandemic. The Company carried out maintenance to the processing plant during the milling suspension, to minimise future maintenance interruptions. The restart follows a review of Northern Ireland / UK government health advice regarding COVID-19, a risk assessment and the introduction of appropriate modifications to working practices. Feedstock for the processing plant is from low grade stock until suitable arrangements...

The shares in Lerøy Seafood Group ASA will be quoted ex-dividend NOK 1.50 per share as from today, 28 May 2020.This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Aksjene i Lerøy Seafood Group ASA noteres eks. utbytte på NOK 1,50 per aksje fra og med i dag den 28.05.2020.Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

COMMUNIQUE DE PRESSE DU 28 MAI 2020OFFRE PUBLIQUE D’ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETEBLUE SOLUTIONSinitiée par la sociétéinitiée parBOLLORÉprésentée parBOLORÉprésentée parMISE A DISPOSITION DE LA NOTE D’INFORMATION ET DU DOCUMENT « AUTRES INFORMATIONS » RELATIF AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LA SOCIETE BOLLORE SEConformément aux dispositions de l’article 231-28 du règlement général de l’AMF, le document « Autres informations » relatif aux caractéristiques, notamment juridiques, financières et comptables de Bolloré SE a été déposé auprès de l’AMF le 26 mai 2020 et est mis à la disposition du public.Ce document ainsi que la note d’information sont disponibles sur les sites Internet de Bolloré SE (www.bollore.com) et de l’AMF (www.amf-france.org) et peuvent être obtenus sans frais...

Reduces infusion time to 2 hours from the conventional 3.5 hours for patients with relapsing or primary progressive multiple sclerosisEMA approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional OCREVUS dosing regimen             Basel, 28 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).AttachmentRoche_mediarelease_Ocrevus_28052020b_EN

May 28, 2020 – Hamilton, BermudaFlex LNG Ltd. (“Flex LNG” or the “Company”) today announced its unaudited financial results for the first quarter and three months ended March 31, 2020Highlights:Revenues of $38.2 million for the first quarter 2020, compared to $52.0 million for the fourth quarter 2019.Net loss of $14.9 million and loss per share of $0.27 for the first quarter 2020, compared to a net income of $23.9 million and earnings per share of $0.44 for the fourth quarter 2019.Average Time Charter Equivalent (“TCE”) rate of $67,740 per day for the first quarter 2020, compared to $94,000 per day for the fourth quarter 2019.Adjusted EBITDA of $27.8 million for the first quarter 2020, compared to $41.6 million for the fourth quarter 2019.Adjusted net income of $9.3 million for the first quarter 2020, compared...

Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer.Basel, 28 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. “As more information about COVID-19 pneumonia becomes available in these unprecedented times, it is more important than ever to work together to fight this disease,” said Levi...